Clare Ozawa
Director at Lycia Therapeutics.
Raised on Lycia Therapeutics filings
$75M
of $75M offered across 1 Form D filing
- Form D filings
- 1
- Teammates
- 6
- Last filing
- Jun 25, 2026
Company
Lycia Therapeutics
Biotech · South San Francisco, CA
Extracellular protein degraders for immune diseases
Extracellular protein degraders for immune diseases
- Investors
- 16
Lycia Therapeutics filings
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jun 25, 2026 | Equity | $75M/ $75M | Form D |
- EquityFiled Jun 25, 2026Form D$75M/ $75M
